%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Fournier, P. E.
%A Houhamdi, L.
%A Colson, P.
%A Cortaredona, Sébastien
%A Delorme, L.
%A Cassagne, C.
%A Lagier, J. C.
%A Chaudet, H.
%A Tissot-Dupont, H.
%A Giraud-Gatineau, A.
%A Fenollar, F.
%A Million, M.
%A Raoult, D.
%T SARS-CoV-2 vaccination and protection against clinical disease : a retrospective study, Bouches-du-Rhone District, Southern France, 2021
%D 2022
%L fdi:010084244
%G ENG
%J Frontiers in Microbiology
%K COVID-19 ; SARS-CoV-2 ; vaccine ; death ; intensive care ; hospitalization ; protective effect
%K FRANCE
%K BOUCHES DU RHONE
%M ISI:000749267300001
%P 796807 [10 ]
%R 10.3389/fmicb.2021.796807
%U https://www.documentation.ird.fr/hor/fdi:010084244
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-03/010084244.pdf
%V 12
%W Horizon (IRD)
%X From January 18th to August 13th, 2021, 13,804 unvaccinated and 1,156 patients who had received at least one COVID-19 vaccine dose were tested qPCR-positive for SARS-CoV-2 in our center. Among vaccinated patients, 949, 205 and 2 had received a single, two or three vaccine doses, respectively. Most patients (80.3%) had received the Pfizer-BioNTech vaccine. The SARS-CoV-2 variants infecting vaccinated patients varied over time, reflecting those circulating in the Marseille area, with a predominance of the Marseille-4/20A.EU2 variant from weeks 3 to 6, of the Alpha/20I variant from weeks 7 to 25, and of the Delta/21A variant from week 26. SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%, p< 10(-3)). Among 161 patients considered as fully vaccinated, i.e., >14 days after the completion of the vaccinal scheme (one dose for Johnson and Johnson and two doses for Pfizer/BioNTech, Moderna and Sputnik vaccines), 10 (6.2%) required hospitalization and four (2.5%) died. Risks of complications increased with age in a nonlinear pattern, with a first breakpoint at 54, 33, and 53 years for death, transfer to ICU, and hospitalization, respectively. Among patients infected by the Delta/21A or Alpha/20I variants, partial or complete vaccination exhibited a protective effect with a risk divided by 3.1 for mortality in patients >= 55 years, by 2.8 for ICU transfer in patients >= 34 years, and by 1.8 for hospitalization in patients >= 54 years. Compared to partial vaccination, complete vaccination provided an even stronger protective effect, confirming effectiveness to prevent severe forms of COVID-19.
%$ 050 ; 052